JNJ74856665 (JNJ-6665) is an orally available, potent and selective DHODH inhibitor with IC50 of 0.4 nM.
JNJ74856665 inhibited proliferation of MOLM-13, OCI-AML3, HL60 and THP-1 AML cell lines with low nanomolar IC50 values in vitro, demonstrated induction of CD11b and CD14 differentiation marker mRNA levels in four cell lines.
JNJ-74856665 mediated significant activity in decreasing leukemic burden and increasing life span across subcutaneous (MOLM-13 and OCI-AML3) and disseminated (MOLM-13) xenografts, respectively, in vivo.
